EMA Adopts a Positive Opinion for a New Route of Administration Together with a New Pharmaceutical Form and a New Strength for Isatuximab By Ogkologos - May 8, 2026 134 0 Facebook Twitter Google+ Pinterest WhatsApp It is a cancer medicine used to treat adult patients with multiple myeloma Source RELATED ARTICLESMORE FROM AUTHOR Enzalutamide Continues to Provide Substantial Long-Term OS Benefit at 8 Years for Patients with Metastatic Hormone-Sensitive Prostate Cancer Metastatic Breast Cancer: ESMO Living Guideline EMA Recommends Extension of Indications for Datopotamab Deruxtecan MOST POPULAR Neoadjuvant Pembrolizumab Associated with Limited Side Effects and High Clinical Activity... January 16, 2023 New hormone treatment for advanced prostate cancer made available in England June 8, 2021 pCR Associated with Improved Survival Outcomes in Patients with Soft Tissue... April 3, 2023 10 Tips for National Cancer Prevention Month February 10, 2021 Load more HOT NEWS Ground-breaking trial pilots new tests to detect lung cancer earlier Severe Side Effects of Cancer Treatment Are More Common in Women... FDA Approves Penpulimab-kcqx for Non-keratinizing Nasopharyngeal Carcinoma FDA Approves Crizotinib for Children and Young Adults with Relapsed or...
